This is not a concrete new development, but a general industry overview.
This approval marks a critical milestone for Innovent, expanding its oncology portfolio in China with a next-generation BTK inhibitor. It offers a new treatment avenue for a patient population with limited options, potentially altering the standard of care for relapsed/refractory CLL and SLL and strengthening Innovent's position in the competitive hematology market.
NMPA approves Jaypirca for relapsed/refractory CLL and SLL in adults
Approval is based on the Phase 3 BRUIN study showing superior progression-free survival
The drug offers a new option for patients who have failed previous BTK inhibitor therapy
The drug offers a new option for patients who have failed previous BTK inhibitor therapy
Innovent strengthens its hematology-oncology presence in China
Sign in to save notes on signals.
Sign In